stoxline Quote Chart Rank Option Currency Glossary
  
Organogenesis Holdings Inc. (ORGO)
2.985  0.015 (0.51%)    04-23 11:00
Open: 2.98
High: 3.0401
Volume: 69,554
  
Pre. Close: 2.97
Low: 2.94
Market Cap: 394(M)
Technical analysis
2024-04-23 10:50:14 AM
Short term     
Mid term     
Targets 6-month :  3.57 1-year :  4.18
Resists First :  3.06 Second :  3.57
Pivot price 2.88
Supports First :  2.74 Second :  2.53
MAs MA(5) :  2.9 MA(20) :  2.84
MA(100) :  3.31 MA(250) :  3.12
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  78.2 D(3) :  69.2
RSI RSI(14): 54
52-week High :  4.7 Low :  1.79
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ORGO ] has closed below upper band by 17.6%. Bollinger Bands are 62.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.04 - 3.06 3.06 - 3.07
Low: 2.87 - 2.88 2.88 - 2.9
Close: 2.95 - 2.97 2.97 - 2.99
Company Description

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Headline News

Mon, 15 Apr 2024
INVA: 3 Biotech Stocks with Potential Gains - Watch or Buy? - StockNews.com

Wed, 10 Apr 2024
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt? - Simply Wall St

Sat, 02 Mar 2024
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2023 Earnings Call Transcript - Yahoo Finance

Fri, 01 Mar 2024
Organogenesis Holdings Inc Down 24.09% To $2.71 After Earnings Meet - InvestorsObserver

Thu, 29 Feb 2024
Organogenesis: Q4 Earnings Snapshot - Quartz

Thu, 29 Feb 2024
Organogenesis Holdings Inc (ORGO) Faces Revenue Decline in Q4 and FY 2023, Aims for Growth in 2024 - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 132 (M)
Shares Float 62 (M)
Held by Insiders 33.3 (%)
Held by Institutions 44.9 (%)
Shares Short 7,230 (K)
Shares Short P.Month 7,570 (K)
Stock Financials
EPS 0.03
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.11
Profit Margin 1.1 %
Operating Margin 0.6 %
Return on Assets (ttm) 2.2 %
Return on Equity (ttm) 1.8 %
Qtrly Rev. Growth -13.7 %
Gross Profit (p.s.) 0
Sales Per Share 3.28
EBITDA (p.s.) 0.24
Qtrly Earnings Growth 0 %
Operating Cash Flow 31 (M)
Levered Free Cash Flow 18 (M)
Stock Valuations
PE Ratio 74.62
PEG Ratio -118.7
Price to Book value 1.4
Price to Sales 0.9
Price to Cash Flow 12.73
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android